- News & Analysis
- Home
- Latest News
- Reports
- Podcast
- The CVC Funding Round Database
- The CVC Directory
- University
- Video
- Subscribe
- Newsletters
- Events
Page 352
i2x identifies MS&AD for $11.4m round
MS&AD Ventures has contributed to a round for i2x, which offers an enhanced speech recognition product that provides automated coaching tips to improve business phone calls.
Feb 28, 2019i2x identifies UVC Partners for $11.4m round
Unternehmertum’s VC affiliate co-led the deal for i2x, which offers an enhanced speech recognition product that provides automated coaching tips to improve business phone calls.
Feb 28, 2019CCS connects to Adtran for $10m
Touchstone Innovations-backed Cambridge Communication System has received $10m in a funding round that included a $5m commitment from Adtran.
Feb 28, 2019Birmingham unis call angel network
University of Birmingham and Aston University have deepened their relationship with Warwick-operated Minerva to start a syndicate targeting businesses in the West Midlands.
Feb 28, 2019CCS connects to Adtran for $10m
Cambridge Communication System has received $10m in a funding round that included a $5m commitment from Adtran.
Feb 28, 2019Aidence detects Rabobank for series A
Rabo Ventures has co-led the artificial intelligence-based medical imaging technology developer's $11.3m series A alongside Inkef Capital.
Feb 28, 2019Yukin yields Satt Sud-Est licences
Satt Sud-Est has licensed Yukin Therapeutics to commercialise patents originating from several French institutions on the back of inventions from regional research hub Canceropôle Provence-Alpes-Côte d'Azur.
Feb 28, 2019OSI welcomes Conn and Pichette
Charles Conn and Patrick Pichette will join Oxford Sciences Innovation to become chief executive and chairman, respectively, with founder Dave Norwood retiring.
Feb 28, 2019Hookipa Pharma develops series D
Immunotherapy developer Hookipa, backed by Gilead, Boehringer Ingelheim and Takeda, has collected $37.5m in a series D round led by Redmile Group.
Feb 27, 2019Anaveon validates Novartis for series A
Zurich immuno-oncology spinout Anaveon raised $35.1m from Novartis Venture Fund and Syncona in addition to seed-stage notes converted by the UZH Life Sciences Fund.
Feb 27, 2019About us
GCV provides the global corporate venturing community and their ecosystem partners with the information, insights and access needed to drive impactful open innovation. Across our three services - News & Analysis, Community & Events, and the GCV Institute - we create a network-rich environment for global innovation and capital to meet and thrive. At the heart of our community sits the GCV Leadership Society, providing privileged access to all our services and resources.
Navigation
test regLogin
Not yet subscribed?
We use cookies to enhance your browsing experience and analyse our traffic. By clicking "Accept All", you consent to our use of cookies. Accept Read MorePrivacy & Cookies PolicyPrivacy Overview
This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.


